Allergy Shots for Dog Allergies: Human SCIT Evidence, Hypoallergenic Myth & Can f 5 Exit Ramp
This page is about allergy shots for HUMANS allergic to dogs — NOT for treating allergies IN your dog. Veterinary products like Cytopoint (Zoetis lokivetmab), Apoquel (Zoetis oclacitinib), and veterinary allergen-specific immunotherapy are different product categories for animal patients — not human treatments. For YOU allergic to a dog, this is the right page. Dog SCIT evidence is 'poor and conflicting' per Smith 2016; 16.5% of dog-sensitized adults can skip shots by adopting female or neutered dogs.
8 peer-reviewed sources
Allergy shots for dog allergies treat HUMANS sensitized to dog dander via subcutaneous immunotherapy (SCIT). Dog extracts are not FDA-standardized; Smith 2016 rated evidence as 'poor and conflicting.' Before SCIT, Can f 5 component testing may reveal a no-shot alternative for 16.5% of patients.
The essentials
This page is about allergy shots for HUMANS allergic to dogs — NOT for treating allergies IN your dog. Veterinary products like Cytopoint (Zoetis lokivetmab, an anti-IL-31 monoclonal antibody injected into the dog every 4–8 weeks for canine atopic dermatitis), Apoquel (Zoetis oclacitinib, an oral JAK inhibitor for the dog ≥12 months), and veterinary allergen-specific immunotherapy (vet ASIT, allergen extract injected INTO the dog) are different product categories for animal patients. For a dog with skin allergies, see a veterinarian. For YOU being allergic to a dog, this is the right page. This page covers human immunotherapy for dog-allergen sensitization.
Dog allergy immunotherapy is the cautionary tale of pet immunotherapy, and patients deserve honesty about the evidence asymmetry. Smith DM and Coop CA (Ann Allergy Asthma Immunol 2016;116:188–193) reviewed 17 trials of dog allergen SCIT and concluded the medical literature shows "poor and conflicting results of clinical efficacy, attributed to poor-quality extracts and the inherent complex allergenic profile of dogs that remains without a clearly dominant allergen." Unlike cat extract (FDA-standardized at 10,000 BAU/mL for cat-hair and cat-pelt under Greer license #308), no FDA-standardized dog extract exists in the US. Dog extracts are PNU-based or w/v with significant lot-to-lot variability.
Dog has at least seven co-dominant allergens. Can f 1 (a 23–25 kDa lipocalin from saliva and dander) is the best single predictor at 42–75% sensitization rates (Konieczny A et al., Immunology 1997), but no single dog allergen exceeds 75% of sensitized patients. This molecular complexity means a given SCIT vial may not contain therapeutically relevant amounts of the allergen(s) actually driving a particular patient's symptoms.
The most actionable molecular finding for dog-allergic patients is the Can f 5 monosensitization exit ramp. Can f 5 is a 28 kDa prostatic kallikrein produced exclusively in the prostate gland of intact male dogs — it is absent in female dogs and neutered males (Mattsson L et al., JACI 2009). Özuygur Ermis SS et al. (Allergy 2023;53:88–104) found that 16.5% of dog-sensitized adults in the West Sweden Asthma Study were monosensitized to Can f 5. Schoos AMM et al. (JACI Pract 2020;8:1592–1597) confirmed in a randomized double-blind placebo-controlled challenge that 7 of 7 Can f 5-monosensitized children had no reaction to female-dog extract. These patients can adopt a female or neutered dog and skip immunotherapy entirely.
The hypoallergenic-breed myth must be addressed directly. Vredegoor JK et al. (JACI 2012;130[4]:904–9) measured Can f 1 in 196 dogs and found "hypoallergenic" breeds had HIGHER Can f 1 — geometric mean 2.26 µg/g versus 0.77 µg/g in non-hypoallergenic breeds (P<0.001). Nicholas CE et al. (Am J Rhinol Allergy 2011) found detectable Can f 1 in 94% of 173 Henry Ford homes regardless of breed. Lockey RF (JACI 2012 editorial) summarized this as "the myth of hypoallergenic dogs (and cats)." Curex pairs at-home IgE component testing with allergist review to distinguish Can f 1 (lipocalin, all dogs), Can f 5 (prostatic kallikrein, intact males only), and Can f 3 (albumin, often a cross-reactivity marker from another mammal) — clinically meaningful because Can f 5-monosensitized patients (16.5% of dog-sensitized adults per Ozuygur Ermis 2023) can adopt a female or neutered dog and skip immunotherapy entirely.
How allergy shots retrain your immune system
Dog allergy shots follow the same general subcutaneous immunotherapy mechanism as other aeroallergen SCIT — repeated controlled exposure to dog allergen extract to shift IgE-driven responses toward IgG4 blocking antibodies and T-regulatory cell tolerance. However, dog extract complexity makes the mechanism less predictable than cat SCIT. Because no single dog allergen exceeds 75% sensitization and standard extracts are not FDA-standardized, the composition of a given dog SCIT vial may not reflect the patient's individual sensitization profile.
Component-Resolved Diagnosis First
Before dog SCIT, a board-certified allergist should test Can f 1, Can f 5, and Can f 3 separately. Can f 5-monosensitized patients (16.5% of dog-sensitized adults per Ozuygur Ermis 2023) may avoid SCIT entirely by adopting a female or neutered dog (Schoos 2020 DBPC).
Build-Up Phase (~26 weeks, weekly)
Injections begin far below the therapeutic dose and increase stepwise over approximately 26 weekly visits. A mandatory 30-minute post-injection observation period is required at every visit per Cox 2011 PP3.
Maintenance Phase (3–5 years, every 2–4 weeks)
The maintenance dose per allergist judgment is sustained at extending intervals. Unlike cat extract, there is no FDA-standardized reference dose for dog SCIT, making therapeutic target-setting more variable between practices.
Reassess at 12 Months
Because dog SCIT evidence is 'poor and conflicting' per Smith 2016, the allergist should reassess clinical response after 12 months at maintenance. If no meaningful improvement is documented, the rationale for continuing should be re-evaluated.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Treatment timeline — phase by phase
Dog SCIT follows the same three-phase structure as other subcutaneous allergen immunotherapy. Year 1 requires approximately 39 in-clinic visits; Years 2–5 require 14–20 visits/year. The evidence for disease-modifying benefit over a full 3-to-5-year course is substantially weaker for dog than for cat allergen.
Weekly injections escalating from a starting fraction to the maintenance dose. A 30-minute post-injection observation period is mandatory at every visit per Cox 2011 PP3 and AAAAI position statement.
Year 1: approximately 39 total in-clinic visits. Years 2–5: 14–20 visits/year. Consistent dosing is critical; gaps beyond 5 weeks require dose reductions. The full course is approximately 95–119 in-clinic visits.
For dog SCIT, post-treatment remission data are sparse compared to the Durham 1999 NEJM grass data. Any residual benefit from a complete dog SCIT course is extrapolated from general SCIT literature rather than dog-specific long-term trials.
Efficacy by allergen — what the data shows
Dog SCIT efficacy evidence is genuinely weak. Smith DM and Coop CA (Ann Allergy Asthma Immunol 2016;116:188–193) reviewed 17 trials and concluded 'poor and conflicting results of clinical efficacy.' This contrasts sharply with cat SCIT (~72% symptom reduction in DBPC RCTs) and grass/dust-mite SCIT (Cochrane SMD −0.73). Patients and allergists should calibrate expectations accordingly.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youTreatment options side by side
Dog-allergic patients have four clinically distinct pathways depending on component sensitization profile: Can f 5 monosensitization (adopt a female/neutered dog, no SCIT needed — the best option for that group), Can f 1-dominant (SCIT, now available either in-office or as an at-home allergy shot kit, or SLIT drops, both with acknowledged weak dog-specific evidence), symptomatic pharmacotherapy alone, or avoidance. The optimal path requires component-resolved IgE testing first.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
At-Home Dog SCIT (Curex) | |||||
SLIT Drops (needle-free, dog-specific) | |||||
Female/Neutered Dog Adoption (Can f 5 monosensitized only) |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
Curex delivers conventional dog SCIT as an at-home allergy shot kit for $129/month all-inclusive — the same dog-extract immunotherapy, with its 'poor and conflicting' evidence limits unchanged, replacing the roughly 39 Year-1 in-clinic visits and 14–20 maintenance visits/year the Cox 2011 Practice Parameter requires. The serum is sterile-compounded to USP <797>, a board-certified allergist oversees the plan and reassesses response at 12 months, your first dose and every dose change are supervised live over Zoom, and a prescribed epinephrine auto-injector is confirmed on hand. Can f 5-monosensitized patients should weigh adopting a female or neutered dog first.
See if at-home shots are right for youSide effects — what to watch for
Dog SCIT shares the same safety profile as all subcutaneous allergen immunotherapy. The mandatory 30-minute post-injection observation period at a clinic equipped to treat anaphylaxis is required at every visit.
Insurance coverage — what to expect
Dog SCIT is covered by major commercial insurers and Medicare Part B when standard medical necessity criteria are met. UnitedHealthcare ended coverage of home-administered SCIT effective January 1, 2023. For full insurer-by-insurer details, see /allergy-shots/cost/does-insurance-cover-allergy-shots.
Skip the insurance hassle — Curex is $129/mo flat, no insurance needed.
Start free assessmentFrequently asked questions
Are Cytopoint and Apoquel for humans allergic to dogs?
No. Cytopoint (Zoetis lokivetmab) is a caninized anti-IL-31 monoclonal antibody injected into dogs every 4–8 weeks for canine atopic dermatitis (the dog's own skin allergy). Apoquel (Zoetis oclacitinib) is an oral JAK inhibitor tablet given to dogs ≥12 months for the same condition. Neither product addresses human IgE sensitization to dog dander. They are prescribed by veterinarians, administered to dogs, and approved by the FDA or USDA for veterinary use only. For humans allergic to dogs, the relevant treatments are subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT) drops administered by a board-certified allergist.
What is the Can f 5 exit ramp and who qualifies?
Can f 5 is a 28 kDa prostatic kallikrein produced exclusively in the prostate gland of intact male dogs — it is absent in female dogs and neutered males (Mattsson L et al., JACI 2009). Approximately 16.5% of dog-sensitized adults in the West Sweden Asthma Study were monosensitized to Can f 5 (Özuygur Ermis SS et al., Allergy 2023;53:88–104). Schoos AMM et al. (JACI Pract 2020;8:1592–1597) confirmed in a randomized DBPC challenge that all 7 Can f 5-monosensitized children showed no reaction to female-dog extract. Clinically, this means Can f 5-monosensitized patients — roughly 1 in 6 dog-sensitized adults — can adopt a female or neutered dog and avoid immunotherapy entirely. A component-resolved IgE test including Can f 5 is the qualifying step.
Why is dog SCIT evidence weaker than cat SCIT?
Two structural reasons explain the evidence gap. First, no FDA-standardized dog allergen extract exists — dog extracts are PNU-based or w/v with significant lot-to-lot variability, making it impossible to guarantee the therapeutic dose of the relevant allergen in any given vial. Second, the dog allergen profile lacks a single dominant allergen: Can f 1 sensitizes 42–75% of dog-allergic patients, but six other co-dominant allergens (Can f 2 through Can f 7) each sensitize additional subsets. This means standard dog SCIT extracts cannot reliably cover the full allergen burden for all patients. Smith DM and Coop CA (Ann Allergy Asthma Immunol 2016;116:188–193) reviewed 17 trials and concluded 'poor and conflicting results' — attributing both problems explicitly.
Do hypoallergenic dog breeds really shed less allergen?
No. Vredegoor JK et al. (JACI 2012;130[4]:904–9) measured Can f 1 in 196 dogs and found that breeds marketed as hypoallergenic — including Labradoodles, Poodles, and Spanish Waterdogs — had HIGHER Can f 1 levels (geometric mean 2.26 µg/g) than non-hypoallergenic breeds (0.77 µg/g; P<0.001). Nicholas CE et al. (Am J Rhinol Allergy 2011) found no significant difference in Can f 1 levels between hypoallergenic and non-hypoallergenic breed homes in 173 Henry Ford households; 94% of all homes had detectable Can f 1. Lockey RF (JACI 2012 editorial) described this as 'the myth of hypoallergenic dogs (and cats).' The narrow exception is the Can f 5 monosensitized patient who can tolerate female or neutered dogs of any breed.
How long do allergy shots for dog allergies take?
Dog SCIT follows the same timeline as other subcutaneous allergen immunotherapy: approximately 26 weekly build-up injections followed by every-2-to-4-week maintenance injections for 3–5 years, per the AAAAI/ACAAI Practice Parameter Third Update (Cox 2011). Year 1 totals approximately 39 in-clinic visits; Years 2–5 require approximately 14–20 visits/year. Total course is approximately 95–119 in-clinic visits. A 30-minute post-injection observation period is required at every visit. Tkacz JP et al. (Curr Med Res Opin 2021;37[6]:957–965; n=103,207) found that 23.9% of AIT patients never returned for the first injection, highlighting the practical challenge of this visit burden for a treatment with uncertain efficacy in dog allergy.
Is there a blood test to know if I need dog allergy shots?
Yes. Component-resolved IgE testing — a blood test that measures IgE to individual molecular components (Can f 1, Can f 2, Can f 3, Can f 5, Can f 6) rather than total dog extract IgE — is the most informative diagnostic step before committing to dog SCIT. Can f 1-positive patients are broadly dog-allergic and may be SCIT or SLIT candidates. Can f 5-monosensitized patients (16.5% of dog-sensitized adults per Özuygur Ermis 2023) can adopt a female or neutered dog instead. Can f 3-dominant patients may be primarily cross-reactive from another mammalian allergen, in which case dog SCIT may be less effective than targeting the true primary allergen. A board-certified allergist interprets component results in the context of your clinical history.
What is the systemic reaction rate for dog allergy shots?
Dog SCIT shares the systemic reaction rate of all subcutaneous allergen immunotherapy: approximately 0.1–0.2% per injection visit (Epstein TG et al., Ann Allergy Asthma Immunol 2014). Fatal anaphylaxis occurs at approximately 1 per 23.3M injection visits across all SCIT allergens. The majority of systemic reactions occur within 30 minutes of injection — the reason administration with a mandatory 30-minute observation period is required at every visit. If you experience throat tightness, difficulty breathing, generalized hives, or lightheadedness after an injection, call 911 immediately and use an epinephrine auto-injector if available.
Related Articles
Weekly Allergy Shots: Schedule & Missed Doses | Curex
Weekly allergy shots are the conventional SCIT build-up: 24–28 visits over 3–6 months. Learn the dose ladder, missed-dose rules per Cox 2011, and why 23.9% drop out.
Read moreAllergy Shots for Cat Allergy | Full SCIT Guide | Curex
Allergy shots for cat allergies reduce symptoms 60-72% at the 15 mcg Fel d 1 maintenance dose. Cat SCIT efficacy, dosing, and alternatives.
Read moreAllergy Shots for Pet Dander | Curex Species Guide
Allergy shots for pet dander treat HUMANS sensitized to cat, dog, horse, or small-mammal allergens. Cat has FDA-standardized extract; dog evidence is 'poor and conflicting.'
Read moreCat Allergy Shots for Humans | Curex SCIT Guide
Cat allergy shots for humans traditionally mean ~95–119 clinic visits over 3–5 years (23.9% quit, Tkacz 2021). Curex delivers that SCIT at home, $129/mo.
Read moreAllergy Desensitization: SCIT Guide & History | Curex
Allergy desensitization is the historical term for SCIT (allergen immunotherapy). Cochrane 51 RCTs: SMD -0.73. Learn the terminology shift from 1911 to today.
Read moreCat Allergy Shots for Humans | Curex SCIT Guide
Cat allergy shots use FDA-standardized Fel d 1 extract for ~72% symptom relief. RCT evidence, schedule, plus at-home SCIT from Curex at $129/mo.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.